Wren raises £18M series A for protein misfolding pipeline

Wren Therapeutics Ltd. (Cambridge, U.K.) raised £18 million ($23.1 million) in a series A round that will allow the company to advance its pipeline of protein misfolding disease candidates.

Spun out from the University of Cambridge and Lund University in 2016, Wren's small molecules and antibodies are being developed to treat and diagnose neurologic, ophthalmologic and metabolic diseases. The company said its technology is focused on the chemical kinetics of the protein misfolding process...